Research led by Dr. David O'Gorman identifies new target in treating Dupuytren's disease.

Dr. David O'Gorman talks to CTV News about new research into the treatment of Dupuytren's disease. Dr. O'Gorman and his team are the first to demonstrate that insulin-like growth factor-II (IGF-II) induces Dupuytren's disease cells to contract, leading to new approaches to treating the disease. The findings of his study, "IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease" were recently published in the October issue of the scientific journal Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

Click on the image above to watch the video on the CTV News website.